#USA #Philadelphia #Clinical Trials #Verismo Therapeutics #KIR-CAR

Verismo Therapeutics Readies for Notable Upcoming Presentations at SITC and ASH Annual Meetings

Verismo Therapeutics, a clinical-stage company specializing in CAR T cell therapy and the innovative KIR-CAR platform, has announced its involvement in two significant medical meetings: the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 and the American Society of Hematology (ASH) Annual Meeting 2025. These gatherings are vital for the development and dissemination of new treatments in the oncology field, making Verismo's participation noteworthy for professionals in the healthcare industry.

Insights from SITC Annual Meeting

Scheduled to take place from November 7 to November 9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, Maryland, the SITC Annual Meeting will feature Verismo's presentations covering new preclinical and translational data from their clinical pipelines, SynKIR™-110 and SynKIR™-310.

The presentations will highlight three main areas of research:
1. Oral and Poster Presentation on SynKIR™-110: This groundbreaking therapy targets mesothelin, and will be showcased via an oral session and a poster presentation. Verismo aims to explain how SynKIR™-110 exhibits an increased safety profile and heightened efficacy both in vitro and in vivo. Presenting this work on November 7, 2025, will be Dr. Nora Yucel, PhD, during the Oral Abstract Session 2.
2. Poster on Immunohistochemistry Detection: Additionally, a poster presented by Dr. Adina Vultur will focus on the immunohistochemical detection of mesothelin to facilitate the development of CAR T cell therapy for cholangiocarcinoma. This poster session will engage attendees on November 8, 2025.
3. Poster on Timeliness in Cell Therapy Manufacturing: Another important aspect of the presentations will include considerations on patient material release. Dr. Jacqueline Stief will present critical information on maintaining quality in the manufacture of autologous cell therapy products, also during the weekend of November 7-8, 2025.

Key Takeaways from ASH Annual Meeting

Following SITC, Verismo will shift focus to the ASH Annual Meeting, which is slated for December 6-9, 2025, at the Orange County Convention Center in Orlando, Florida. At this event, the research team plans to present a poster examining the robust antitumor effects of SynKIR™-310, a CD19-targeted therapy, as demonstrated in preclinical mouse models. This promising approach aims to enhance patient responses in B cell malignancies and will be presided over by Dr. Megan Blair during the session on December 7, 2025.

About Verismo Therapeutics

Verismo Therapeutics operates as a subsidiary of HLB Innovation, leading the charge in developing multi-chain KIR-CAR technologies represented by their assets, SynKIR™-110 and SynKIR™-310. Both treatments are currently undergoing Phase 1 clinical trials, focusing on addressing significant unmet medical needs, such as advanced solid tumors and B cell-related disorders.

Conclusion

As the oncology landscape continues to evolve, the advancements presented by Verismo Therapeutics at these critical annual meetings could pave the way for new therapies that enhance patient care and treatment outcomes. Their unique KIR-CAR platform harnesses NK cell-derived receptors, potentially offering extended persistence and reduced exhaustion of T cells, which are crucial for combatting resistant tumors.

For additional insights into Verismo Therapeutics and their innovative approaches to cancer treatment, please visit their official website.